Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459213 | 0.86 | NOS1 (0.41) | PIM1PIM3PIM2RETLRRK2 | |
| SCHEMBL9883364 | 0.71 | LRRK2 (0.43) | PIM1PIM3PIM2LRRK2 | |
| SCHEMBL10459260 | 0.70 | PIM1 (0.41) | PIM1PIM3PIM2LRRK2SYK | |
| SCHEMBL10459276 | 0.70 | PIM1 (0.43) | PIM1PIM3PIM2LRRK2SYK | |
| SCHEMBL1833053 | 0.70 | LRRK2 (0.44) | PIM1PIM3PIM2LRRK2 | |
| SCHEMBL10459247 | 0.68 | PIM1 (0.43) | PIM1PIM3PIM2LRRK2SYK | |
| SCHEMBL10459404 | 0.67 | PIM1 (0.50) | PIM1PIM3PIM2LRRK2 | |
| SCHEMBL1639739 | 0.66 | LRRK2 (0.67) | PIM1PIM3PIM2LRRK2NTRK1 | |
| SCHEMBL10459165 | 0.65 | PIM1 (0.61) | PIM1PIM3PIM2SYK | |
| SCHEMBL10457547 | 0.65 | CYP2D6 (0.53) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885PIM3 363/4885PIM2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.